SCHEMBL10041690

SCHEMBL10041690

Clc1ccc(Cl)c(-c2cc3ccccc3nc2-c2nc3ccccc3[nH]2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.54
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
ALDH1A1 P00352 5/20 0.54
GPR55 Q9Y2T6 1/20 0.54
AMY1A P0DUB6 1/20 0.47
TP53 P04637 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KDR P35968 2/20 0.46
PDGFRB P09619 1/20 0.46
FGFR1 P11362 1/20 0.46
HSD17B10 Q99714 3/20 0.45
PKM P14618 3/20 0.45
ABCB11 O95342 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HPGD P15428 3/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14644256 0.90 NPC1 (0.57) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL14644096 0.85 NPC1 (0.61) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL12861171 0.83 ALDH1A1 (0.71) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL10041654 0.82 ALDH1A1 (0.69) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL14644293 0.82 NPC1 (0.54) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL10041703 0.79 NPC1 (0.56) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL28874978 0.78 NPC1 (0.60) KDM4ENPC1RAB9AALDH1A1TP53
SCHEMBL14643664 0.78 KDM4E (0.51) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL10041685 0.76 NPC1 (0.59) KDM4ENPC1RAB9AALDH1A1GPR55
SCHEMBL10041699 0.76 ALDH1A1 (0.72) KDM4ENPC1RAB9AALDH1A1GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139562-B2 Nitrogen-containing heterocyclic compound and organic electronic device using the same LG CHEM, LTD. (KR) 2015-09-22 US disclosed
US-9139562-B2 Nitrogen-containing heterocyclic compound and organic electronic device using the same LG CHEM, LTD. (KR) 2015-09-22 US disclosed
US-8368062-B2 Nitrogen-containing heterocyclic compound and organic electronic device using the same LG CHEM, LTD. (KR) 2013-02-05 US disclosed
US-8368062-B2 Nitrogen-containing heterocyclic compound and organic electronic device using the same LG CHEM, LTD. (KR) 2013-02-05 US disclosed
US-20120007069-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME LG CHEM, LTD. (KR) 2012-01-12 US disclosed
US-20120007069-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME LG CHEM, LTD. (KR) 2012-01-12 US disclosed
US-20110127513-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME LG CHEM, LTD. (KR) 2011-06-02 US disclosed
US-20110127513-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME LG CHEM, LTD. (KR) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120007069-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME VDAC2, VDAC1, VDAC3 KDM4E 382/4885NPC1 3498/4885RAB9A 2658/4885
US-20110127513-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ORGANIC ELECTRONIC DEVICE USING THE SAME VDAC2, VDAC1, VDAC3 KDM4E 382/4885NPC1 3498/4885RAB9A 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.